Home Cart Sign in  
Chemical Structure| 104376-79-6 Chemical Structure| 104376-79-6

Structure of Ceftriaxone sodium hydrate
CAS No.: 104376-79-6

Chemical Structure| 104376-79-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ceftriaxone Sodium Hydrate is the third-generation cephalosporin useful for the treatment of a number of bacterial infections.

Synonyms: Ro 13-9904 sodium hydrate; Ceftriaxone(sodium salt hydrate); Rosihlitazone

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ceftriaxone sodium hydrate

CAS No. :104376-79-6
Formula : C18H30N8Na2O14S3
M.W : 724.65
SMILES Code : CN1C(SCC(CS[C@]2([H])[C@@](/N=C([O-])/C(C3=CSC(N)=N3)=N\OC)([H])C4=O)=C(N42)C([O-])=O)=NC(C(N1)=O)=O.[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[Na+].[Na+]
Synonyms :
Ro 13-9904 sodium hydrate; Ceftriaxone(sodium salt hydrate); Rosihlitazone
MDL No. :MFCD01750405

Safety of Ceftriaxone sodium hydrate

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H315-H319-H317-H334
Precautionary Statements:P501-P261-P285-P264-P280-P272-P342+P311-P337+P313-P305+P351+P338-P304+P341-P302+P352-P333+P313-P362

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
THP-1 monocytes 4 mg/L 7 days Evaluated the bactericidal effect of ceftriaxone on intracellular MAC, showing EC50 of 0.20-0.25 times MIC and maximal kill of 1.16-1.96 log10 CFU/mL. PMC11326821

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Male Sprague Dawley rats Cocaine self-administration followed by abstinence model Intraperitoneal injection 100 and 200 mg/kg Once daily for 6 days To investigate the effects of ceftriaxone on context-primed relapse following abstinence and its impact on AMPA receptor subunit expression in the NAc. Results showed that both doses of ceftriaxone attenuated relapse and reduced GluA1 expression in the NAc, but did not affect GluA2 expression. PMC4762719
Sprague-Dawley rats 6-hydroxydopamine (6-OHDA) Parkinson’s disease model Intraperitoneal injection 200 mg/kg Seven consecutive daily injections Ceftriaxone increased GLT-1 expression and glutamate uptake, reduced tyrosine hydroxylase (TH) loss induced by 6-OHDA, and decreased amphetamine-induced rotation behavior. PMC4618839
Sprague-Dawley rats Subcutaneous injection model Subcutaneous injection 1000 mg/kg Once daily for 12 days To evaluate the local tolerability of subcutaneous ceftriaxone administration. Results showed that the local tissue response was remarkably reduced when the same ceftriaxone dose was given at a lower concentration (25 mg/ml) over a longer period of time (120 min). PMC7038272
Swiss albino mice Cecal ligation and puncture (CLP)-induced sepsis model Subcutaneous injection 100 mg/kg Single dose, 3 hours post-CLP To evaluate the protective effect of ceftriaxone in a sepsis model, results showed that ceftriaxone alone reduced bacterial load but did not significantly improve survival. PMC7224120
Mice Tsc1GFAPCKO mouse model Intraperitoneal injection 200 mg/kg Daily until death or the pre-defined endpoint of the experiment Early treatment (before seizure onset) increased astrocyte glutamate transporter expression, decreased extracellular glutamate levels, neuronal death, and seizure frequency, and improved survival; late treatment (after seizure onset) increased glutamate transporter expression but had no effect on seizures. PMC2823985
Mice Epilepsy model Intraperitoneal injection 200 mg/kg Daily Evaluate the antiepileptic effect of ceftriaxone in epilepsy models PMC5294855
Mice Pneumococcal meningitis model Intraperitoneal 100 mg/kg Daily starting from 16 hours after infection To evaluate the therapeutic effect of ceftriaxone on pneumococcal meningitis, results showed no significant difference in mortality between the ceftriaxone-treated group and the placebo group. PMC6935240
BALB/c mice Systemic lupus erythematosus model Oral gavage 400 mg/kg Once daily for 5 consecutive days To reduce pre-existing bacteria populations to boost the proliferation of intestinal microorganisms from donor animals post-FMT PMC8472682
BALB/c mice Vaginal infection model Intraperitoneal 15 mg/kg Single dose To evaluate the therapeutic effect of ceftriaxone on vaginal infection in mice, results showed all mice cleared the infection within 24 hours after treatment. PMC5039091

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00002052 HIV Infections ... More >> Salmonella Infections Less << Not Applicable Completed - United States, California ... More >> Los Angeles County - USC Med Ctr Los Angeles, California, United States, 90033 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.38mL

0.28mL

0.14mL

6.90mL

1.38mL

0.69mL

13.80mL

2.76mL

1.38mL

References

 

Historical Records

Categories